Medtronic Biz Pleads Guilty In Off-Label Marketing Case
A Medtronic subsidiary has agreed to plead guilty for off-label marketing activities that occurred prior to Medtronic's acquisition. Overall, the firm says it has settled three investigations with a total pay-out of $50.9m. US FDA is underscoring the case as an example of the agency pursuing companies that "put profit over safety."
You may also be interested in...
The US Department of Justice collected $2.8bn in settlements and judgments involving violations of the False Claims Act in 2018, including $2.5bn in health-care cases. Key device industry recoveries included $33.2m from Alere, $12.5m from Angiodynamics, and $30m in two separate settlements from Covidien and its subsidiary ev3.
A ruling from the First Circuit suggests that plaintiffs can’t prove manufacturers violated the False Claims Act by suggesting FDA submissions were fraudulent, if FDA itself hasn’t taken any action against the manufacturer.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.